Related Experiment Video
Updated: Feb 13, 2026

Orthotopic Mouse Model of Colorectal Cancer
Published on: December 4, 2007
Immunotherapy in colorectal cancer: for the select few or all?
Sukeshi Patel Arora1, Devalingam Mahalingam1
1University of Texas Health Science Center San Antonio, 7979 Wurzbach Rd, MC8026, San Antonio, TX 78229, USA.
Abstract:
Over the past few years, the role of immunotherapy in colorectal cancer (CRC) has expanded, specifically in subsets of CRC with microsatellite instability (MSI) for which newer agents, such as programmed death-1 (PD-1) inhibitors, are efficacious. While other immunotherapeutic agents are more immature in development, they have the potential to enhance the efficacy of PD-1 inhibitors and play a role in the treatment algorithm for all subsets of CRC patients. In this review, we will discuss immunotherapeutic agents in development in patients with CRC. We will review the later phase studies that elucidate the role of immunotherapy in CRC and provide hope for changing the treatment paradigm for CRC in the future.
Related Concept Videos
Tumor Immunotherapy
What is Natural Selection?
Antibiotic Selection
Types of Selection
Frequency-dependent Selection
Natural Selection and Adaptation
Beyond physical adaptations,...

